1.. Introduction {#s2}
================

Cognitive impairment is common in geriatric depression.[@b1],[@b2] Some authors suggest that the cognitive impairment in geriatric depression does not improve with remission of depression, and it may even progress to fully-blown dementia.[@b3] One rationale for such a relationship is that Alzheimer\'s Disease and late-onset depression share a common genetic risk factor, the epsilon 4 allele of the apolipoprotein E gene (APOE).[@b4],[@b5] It remains unclear if the cognitive impairment seen in some geriatric patients with depression is independent of depressive symptoms, one of the symptoms of the depressive episode, or both. We hypothesize that the cognitive impairment seen in patients with geriatric depression persists after depressive symptoms resolve, particularly in those with the epsilon 4 allele of APOE. To assess this hypothesis we classified elderly individuals with a first episode of depression into those with and without co-occurring mild cognitive impairment (MCI) and then followed the one-year trajectory of cognitive and depressive symptoms in these patients as they received antidepressant treatment for their depression.

2.. Methods {#s3}
===========

2.1. Sample identification {#s3a}
--------------------------

The flowchart for the study is shown in [Figure 1](#sap-25-02-099-g002){ref-type="fig"}. This is a prospective study of patients with first-onset geriatric depression who sought outpatient or in patient treatment at the Third People\'s Hospital of Huzhou from January 2009 to December 2010. Included patients were at least 60 years of age, met diagnostic criteria for depression specified in the *3^rd^ edition of the Chinese Classification of Mental Disorders* (CCMD-3),[@b6] had a score of at least 11 on the Geriatric Depression Scale (GDS),[@b7] had had no prior episode of depression, had no history of alcohol or drug dependence, had no serious medical condition (including neurodegenerative disorders, cerebrovascular disease, or serious diseases of the heart, liver or kidney) and signed a consent form to participate in the study. The 64 enrolled patients who completed the 12-month follow-up included 17 males and 47 females with a mean age of 67.5 (s.d.=6.0) years and a mean duration of education of 8.9 (4.2) years.

![Flowchart for the study](sap-25-02-099-g002){#sap-25-02-099-g002}

The criteria proposed by Petersen[@b8] were used to identify depressed patients with MCI: (a) impaired memory reported by the patient or their relatives; (b) a memory test score of at least 1.5 standard deviations lower than normal controls with the same age and educational level; (c) a grade of 2 to 3 in the Global Deterioration Scale (GDS)[@b9]; (d) normal general cognitive functioning and daily functioning with an Activity of Daily Living (ADL)[@b8] score lower than 26; and (e) no diagnosis of dementia or any other physical or mental illness that may lead to brain dysfunction. Among the 64 patients with geriatric depression who completed the 12-month follow-up, 30 (46.9%) met these criteria for MCI.

Control subjects were recruited from patients 60 years or older seeking a routine physical examination at the Geriatric Department or the Physical Examination Center of the Third People\'s Hospital of Huzhou. Individuals with a serious physical illness, those who met the above criteria for depression or MCI and those with a family history of depression, dementia or MCI in first-degree relatives were excluded. The 31 recruited controls, all of whom signed consent forms, included 13 males and 18 females, had a mean age of 68.2 (8.6) years and a mean duration of education of 9.0 (4.0) years. There were no statistically significant differences between patients and controls in age (*t=*-0.415, p=0.687), gender (*χ*^2^=2.28, *p*=0.131), or years of education (*t*=-1.09, *p*=0.280).

2.2. Assessment and treatment {#s3b}
-----------------------------

Study participants were administered the GDS, the Mini-Mental State Exam (MMSE),[@b10] the forward and backward digit span task, and the Trail-Making Tests A and B (TMT-A, TMT-B)[@b11] at baseline and the patient group was re-administered these tests after 12 months of treatment with antidepressant medication. All tests were independently administered by two senior attending doctors. Their inter-rater reliability for the various scales was good; the intraclass coefficient (ICC) for MMSE was 0.84, that for the digit span tests was 0.85, that for the TMT-A and TMT-B tests was 0.85, and that for the GDS was 0.88.

In the morning of the day of enrolment, two milliliters of blood was drawn from all participants. These samples were stored at -80 °C and the TIANamp Genomic DNA Kit (DP304) was used for DNA extraction to identify the epsilon 4 isoform of the APOE gene. The TaKaRa LA Taq with GC Buffer (DRR02AG) and BIO-RAD MJ Mini Opticon Real-Time Polymerase Chain Reaction (PCR) System was used for the extraction, the PCR primer was made by Invitrogen (Shanghai), and the PCR sequencing was completed by the Shanghai Majorbio Bio-Pharm Technology Company.

The depressed patients were treated according to the Treatment and Prevention Guidelines for Depressive Disorder of China (issued by the Chinese Medical Association in 2006).[@b12] All patients were treated with selective serotonin reuptake inhibitors (SSRIs) at adequate dosages for sufficient time. After initial titration of the dosage, the dosages remained stable throughout the acute, continuation and maintenance phases of treatment. The first choice of SSRI was not effective after 6 weeks of treatment (i.e., decrease in GDS \<50%) in 19 of the 64 (29.7%) patients so they were converted to a different SSRI; 9 of these patients (14.1%) had still not improved at the end of the 12 months of follow-up. The first line medications used were sertraline (50 to 150 mg/d) or citalopram (20 to 60 mg/d) and the second-line medication was paroxetine (20 to 40 mg/d). After 12 months most patients had completed their full course of antidepressant treatment, only 21 of the 64 patients (32.8%) were still using antidepressant medication at the 12-month follow-up.

This study was approved by the ethical review committee of the Third Hospital of Huzhou.

2.3. Statistical analysis {#s3c}
-------------------------

All analyses were conducted using SPSS (version 17.0) software. Chi-squared test, t-test, repeated measures ANOVA, and Spearman correlation coefficients were used for data analysis. All tests were two-tailed and statistical significance was set as *p*\<0.05.

3.. Results {#s4}
===========

3.1. Comparison of cognitive functioning at baseline {#s4a}
----------------------------------------------------

As shown in [Table 1](#sap-25-02-099-t01){ref-type="table"}, compared to the control subjects the depressed patients had significantly lower total scores on the MMSE, shorter digit spans and took longer to compete the trail making tests. Thus, the depressed patients were more cognitively impaired than control subjects of the same age and gender.

###### Comparison of cognition functioning between 64 patients with geriatric depression and 31 controls at baseline (mean \[SD\])

              Mini Mental Status Exam (score)   Digit Span Tasks (number)   Trail-Making Tests (seconds)                             
  ---------- --------------------------------- --------------------------- ------------------------------ ------------ ------------- --------------
  Patients              28.0 (2.2)                      7.4 (1.3)                    4.6 (1.0)             12.0 (1.9)   71.5 (20.9)   127.2 (44.9)
  Controls              29.9 (0.3)                      8.4 (1.0)                    6.7 (1.2)             15.0 (1.6)   54.4 (16.0)   85.3 (27.2)
   t-value                 -6.87                          -3.89                        -8.95                 -7.63         4.47           4.62
   p-value                \<0.001                        \<0.001                      \<0.001               \<0.001       \<0.001       \<0.001

^a^ The TMT-B test was completed by 48 patients and 23 controls

3.2. Comparison of depressive symptoms and cognitive functioning in depressed elderly with and without MCI before and after treatment {#s4b}
-------------------------------------------------------------------------------------------------------------------------------------

As shown in [Table 2](#sap-25-02-099-t02){ref-type="table"}, the severity of depression at baseline was not statistically different between elderly depressed subjects with and without concurrent MCI. After 12 months of treatment for depression the severity of depression improved significantly in both types of patients but those with concurrent MCI at baseline had significantly more residual symptoms of depression after 12 months of treatment than patients who did not have concurrent MCI at baseline. The magnitude of the change in the before versus after GDS score was smaller in the MCI group, but this difference did not reach statistical significance (*p*=0.065).

###### Comparison of the depressive and cognitive measures between elderly depressed patients with and without mild cognitive impairment (MCI) at baseline and 12 months after initiating treatment for depression (mean \[SD\])

                                Baseline assessment   12-month follow-up   Before v after change score                                                                                                     
  ---------------------------- --------------------- -------------------- ----------------------------- --------- ----------------- ---------------- ------- --------- ------------- ------------- ------- ---------
  Geriatric Depression Scale        20.6 (2.6)            20.6 (2.5)                  0.07                0.944     9.5 (3.3)^a^      7.7 (3.4)^a^    2.15     0.035    11.2 (4.2)    12.9 (3.4)    -1.88    0.065
  Mini-Mental Status Exam            25.8(1.1)            29.9 (0.2)                 -19.75              \<0.001    27.6 (3.1)^a^      29.1 (1.5)     -2.42    0.020     1.7 (3.1)    -0.9 (1.4)    4.40    \<0.001
  Forward digit span                 6.8(1.1)             7.9 (1.2)                   -3.90              \<0.001    7.6 (1.0)^a^       8.2 (1.0)      -2.59    0.012     0.8 (1.2)     0.3 (1.0)    1.88     0.065
  Backward digit span                4.1(1.0)             5.0 (0.8)                   -4.07              \<0.001      4.9 (1.1)       6.1 (1.2)^a^    -4.10   \<0.001    0.9 (1.0)     1.1 (1.5)    -0.70    0.488
  Trail-Making Test-A               71.3(18.8)           71.8 (17.9)                  -0.11               0.914    56.4 (14.3)^a^    52.6 (14.8)^a^   1.04     0.305    14.9 (15.6)   19.2 (15.9)   -1.08    0.282
  Trail-Making Test-B              133.4 (42.7)          109.0 (37.0)                 2.46                0.017    103.9 (28.5)^a^   91.5 (14.8)^a^   2.23     0.029    29.4 (32.0)   17.5 (26.7)   1.63     0.109

^a^ Statistically significant difference between the baseline and the 12 month follow-up result using repeated measure ANOVA, *p*\<0.01

With the exception of the TMT-A test, all of the cognitive measures assessed showed significantly greater impairment in the MCI group at baseline and these differences persisted after 12 months of treatment for depression. In most cases the individual cognitive tests improved over the 12 months in both the MCI group and the non-MCI group, but the improvement in the backward digit span for the MCI group did not reach statistical significance, the improvement in the forward digit span for the non-MCI group did not reach statistical significance, and the total MMSE score in the non-MCI group showed a non-significant decrease over the 12 months. The improvement in the MMSE score over the 12 months was significantly greater in the MCI group than in the non-MCI group, but there were no significant differences in the magnitude of the improvement between the two groups in any of the other cognitive measures.

3.3. Correlation between severity of depression and cognitive functioning before and after treatment {#s4c}
----------------------------------------------------------------------------------------------------

As shown in [Table 3](#sap-25-02-099-t03){ref-type="table"}, prior to treatment the severity of depression was only weakly correlated with the severity of cognitive impairment as measured by the different scales. Twelve months after initiating antidepressant therapy the residual level of depressive symptoms was significantly associated with the severity of three of the five cognitive measures (MMSE, forward digit span and backward digit span).

###### Correlation of cognitive measures with severity of depression (using Geriatric Depression Scale score) among 64 patients with geriatric depression at baseline and 12 months after initiating treatment for depression

                                                             Mini Mental Status Exam   Digit Span   Trail Making Test          
  ----------------------------------------------- --------- ------------------------- ------------ ------------------- ------- -------
  Baseline                                            r               -0.10              -0.24            -0.11         0.16    0.16
  p                                                 0.419             0.058              0.374            0.202         0.220  
  12-month follow-up                                  r               -0.47              -0.26            -0.38         0.20    0.15
  p                                                \<0.001            0.039              0.002            0.107         0.247  
  Before v. after change in score (improvement)       r               0.20                0.05            0.18          0.15    -0.08
  p                                                 0.121             0.675              0.166            0.239         0.544  

3.4. Prevalence of epsilon 4 allele of the APOE genotype and its relationship to the severity of depression and cognitive functioning before and after treatment in depressed subjects {#s4d}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Among the depressed patients 14.1% (9/64) had the epsilon 4 allele of the APOE genotype but only 3.3% (1/30) of the control subjects had this allele (Fisher\'s Exact Test, *p*=0.158). [Table 4](#sap-25-02-099-t04){ref-type="table"} compares the depressive and cognitive symptoms between the 9 patients with geriatric depression who had the epsilon 4 allele and the 55 patients who did not have the allele. At baseline and at the 12 month follow-up the severity of depressive symptoms between those with and without the APOE epsilon 4 allele was similar. Both types of patients showed significant improvements in depressive symptoms with treatment; the magnitude of improvement was slightly greater in those without the allele but this difference was non-significant (*p*=0.164).

At baseline the MMSE and digit span tests results were not significantly different between those with and without the APOE epsilon 4 allele, but those with the allele took significantly longer to complete the TMT-A and TMT-B tests. At the 12-month follow-up all cognitive tests improved in the depressed patients who did not have the APOE epsilon 4 allele, but in the subgroup with the epsilon 4 allele only the two trail-making tests showed significant improvement; the two digit span tests in those with the epsilon 4 allele showed non-significant improvement and the MMSE showed non-significant deterioration. At the end of the 12 months the MMSE score, the backward digit test and the TMT-A test were significantly worse in the subgroup with the epsilon 4 allele than in the subgroup without the allele. The magnitude of improvement in the MMSE score over the 12 months was significantly greater in those without the allele, but there were no significant differences in the magnitude of improvement between the two subgroups for any of the other cognitive measures.

###### Comparison of the depressive and cognitive measures between elderly depressed patients with and without the ApoE4 genotype (mean \[SD\])

                                Baseline assessment   12-month follow-up   Before v. after change score                                                                                                 
  ---------------------------- --------------------- -------------------- ------------------------------ ------- ----------------- ---------------- ------- ------- ------------- ------------- ------- -------
  Geriatric Depression Scale        19.2 (2.6)            20.8 (2.3)                  0.672               0.504    8.8 (2.1)^a^      8.5 (3.7)^a^    -0.26   0.798   10.4 (3.6)    12.4 (3.9)    1.41    0.164
  Mini-Mental Status Exam           27.6 (1.9)            28.1 (2.3)                   1.82               0.074     26.0 (4.2)      28.8 (1.9)^a^    3.33    0.001   -1.6 (3.9)     0.7 (2.4)    2.36    0.021
  Forward digit span                 7.0 (0.9)             7.5(1.3)                    1.39               0.186      7.4 (0.7)       8.0 (1.0)^a^    1.58    0.119    0.4 (1.0)     0.6 (1.1)    0.25    0.800
  Backward digit span                4.1(1.5)             4.6 (0.9)                    1.05               0.321      4.3(1.2)        5.8 (1.2)^a^    3.37    0.001    0.2 (1.1)     1.1 (1.3)    1.95    0.055
  Trail-Making Test-A               84.4 (7.6)           69.4 (18.6)                  -2.38               0.020    61.3 (8.3)^a^    53.2 (15.1)^a^   -2.36   0.030   23.1 (13.7)   16.2 (16.0)   -1.22   0.226
  Trail-Making Test-B              155.0 (49.4)          114.8 (37.4)                 -2.86               0.006   109.8 (25.2)^a^   95.3 (22.2)^a^   -1.78   0.079   45.2 (49.3)   19.5 (23.9)   -1.54   0.160

^a^ Statistically significant difference between the baseline and the 12 month follow-up result using repeated measure ANOVA, *p*\<0.01

4. Discussion {#s5}
=============

4.1. Main findings {#s5a}
------------------

We found that patients who meet criteria for geriatric depression have substantial impairments in their cognitive functioning as assessed by the MMSE, digit span tasks and the Trail-Making tests. Using the criteria specified by Peterson[@b8] 48% of them (31/64) met criteria for MCI. These findings are similar to those of other studies that find impairments in memory and executive function in elderly individuals with depression,[@b13],[@b14] which may be related structural and functional impairments in the hippocampus in persons with depression.[@b15]

We also found that both depressive and cognitive symptoms of elderly individuals with depression improve with standardized treatment for depression with SSRIs. Thus our initial hypothesis that cognitive symptoms in depressed elderly get worse and may progress to full-criteria dementia during antidepressant treatment was not supported, at least for the first year after initiation of antidepressant treatment. When subdividing the depressed group into those with and without MCI at baseline, there were more residual depressive and cognitive symptoms in the MCI group than in the non-MCI group after treatment, but the magnitude of the before-versus-after improvement in the MMSE score (the most comprehensive measure of cognitive functioning used in the study) was actually greater in the MCI group. This suggests that the cognitive symptoms in depressed elderly have both trait (i.e., long-lasting symptoms that may be markers of subsequent dementia) and state (i.e., symptoms that are amenable to treatment) components. Our findings are similar to those of Yuan and colleagues[@b16] who report that the responsiveness of depressive symptoms to antidepressant treatment is less marked in depressed elderly with prominent cognitive symptoms, and to those of Zhang and colleagues[@b17] who report partial improvement of cognitive symptoms in depressed elderly during antidepressant treatment. A study by Butters and colleagues[@b18] also found partial improvement in the comorbid cognitive symptoms of depressed elderly; but their study suggested that problems with executive functioning in these patients were more likely to be treatment resistant, a finding that we did not confirm.

The patients with geriatric depression were more likely to have the APOE epsilon 4 allele than individuals in the control group (a non-significant difference), but there were only 9 patients with the allele so our results must be considered preliminary, needing confirmation in larger samples that have more patients with the APOE epsilon 4 allele. Our results suggest that some cognitive functions are more severely impaired in depressed elderly who have the epsilon 4 allele than in depressed elderly without the allele both before and after antidepressant treatment. Moreover, the MMSE score in patients with the APOE epsilon 4 allele decreased over the year of treatment while the corresponding score in patients without the allele increased. The APOE epsilon 4 allele is considered a predisposing gene for sporadic AD,[@b5] so the presence of this allele in individuals with geriatric depression may mean that more of the comorbid cognitive symptoms are 'trait' symptoms that are not amenable to antidepressant treatment

4.2. Limitations {#s5b}
----------------

The patients identified in this study were those who came to a psychiatric outpatient center for treatment, so they were probably more severely depressed than most elderly depressed individuals in the community. We only used a small number of cognitive tests and did not conduct neuroimaging tests so we were limited in our ability to interpret the underlying pathophysiology related to our findings. Most of the depressed patients had completed their course of treatment at the time of the 12-month follow-up so the post-treatment results combined those of patients who were and were not currently taking antidepressants. The sample size was sufficient to compare cognitive measures between depressed patients and normal controls, and to compare depressive symptoms and cognitive functioning before and after treatment in the depressed patients, but the analyses comparing the outcomes for depressed patients who did and did not have MCI and for patients who did and did not have the APOE epsilon 4 allele was inconclusive because of the small number of depressed patients in the subgroups. The analyses comparing these subgroups in which there were significant differences are valid, but the analyses in which there were non-significant differences between subgroups may have been due to Type II errors.

4.3. Significance {#s5c}
-----------------

Individuals who meet criteria forgeriatric depression treated in outpatient psychiatric clinics in China have substantial cognitive deficits compared to elderly controls without depression; almost one-half of these individuals met criteria for mild cognitive impairment (MCI). The severity of depression in depressed geriatric patients with and without comorbid MCI are similar before treatment and both subgroups of patients improve significantly with antidepressant treatment, but those with comorbid MCI have more residual depressive symptoms at the end of treatment. The cognitive symptoms in both groups also improve during treatment for depression; in most cases the improvement in cognitive symptoms is greater in the patients with comorbid MCI but at the end of one year patients who had MCI at baseline still have significantly greater cognitive deficits than those who did not have MCI at baseline.

Only 9 of the depressed elderly patients in this study had the APOE epsilon allele so it is not possible to come to any definitive conclusions about its role in depression and dementia. Nevertheless, despite depressive symptoms of similar severity in patients with and without the APOE epsilon allele, several of the cognitive measures assessed were significantly worse in patients with the allele both before and after antidepressant treatment and the magnitude of improvement in the MMSE (the main measure of cognitive functioning) with treatment was significantly smaller in those with the allele.

Authors would like to thank Professor Chen Wei from the Run Run Shaw Hospital, Zhejiang University, for his valuable comments.

**Conflict of Interest:** The authors report not conflict of interest related to this manuscript.

**Funding:** The current study is funded by the Huzhou ministry of technology general research funds (2010C33015).

Dr. Zheli Chen graduated from Wenzhou Medical College in 2002 and received a Master\'s of Medicine degree from Suzhou University in 2012. She has worked at the Third Hospital of Huzhou since 2002 in the Department of Geriatric Psychiatry where she is currently an attending psychiatrist. Her main research interests are the clinical characteristics and cognitive functioning of geriatric depression and the early identification and treatment of Alzheimer\'s Disease.
